15. Amgen, Inc. (NASDAQ:AMGN)
Amgen, Inc. (NASDAQ:AMGN) is a $127 billion biopharmaceutical company that had revenue of nearly $23 billion last year and GAAP EPS of $10.24, with those figures having increased by 6% and 13%, respectively. The company’s best-selling drugs are Enbrel and Neulasta, with sales of $5.97 billion and $4.65 billion, respectively. Amgen, Inc. (NASDAQ:AMGN)’s stock is up by almost 15% since the beginning of the year and there were 64 investors in our database long its shares heading into the second quarter of 2017. For its fiscal 2017, Amgen expects revenue of $22.3 billion to $23.1 billion.